mRNA疫苗技术和产业发展概况  

Overview of mRNA Vaccine Technology and Industry Development

作　　者：刘财旺 龙新华 包嫄 李薇 LIU Cai-wang;LONG Xin-hua;BAO Yuan;LI Wei(Yuxi Walvax Biotechnology Co.Ltd;Yunnan Walvax Biotechnology Co.Ltd)

机构地区：[1]玉溪沃森生物技术有限公司 [2]云南沃森生物技术股份有限公司

出　　处：《中国食品药品监管》2023年第12期74-84,共11页China Food & Drug Administration Magazine

摘　　要：近年来,mRNA修饰技术及递送技术的发展很大程度上解决了mRNA疫苗稳定性差及体内递送低效的问题。基于制造简单、研产速度快,安全性高、免疫原性好等优势,mRNA疫苗在抗击COVID-19大流行过程中发挥了重要作用。截至目前,已有多个针对新冠病毒(SARS-CoV-2)的mRNA疫苗获批上市或被授权紧急使用。此外,mRNA疫苗在其他传染病、肿瘤免疫等领域的研发及产业化也成为近期研究热点。本文总结了mRNA疫苗研发管线以及供应链方面的发展状况,期望为后续mRNA疫苗开发和产业化提供参考。In recent years,significant progress in mRNA modification and delivery technologies has largely solved the issues of poor stability and inefficient in vivo delivery of mRNA vaccines.Leveraging advantages such as simplicity in manufacturing,rapid research and production,high safety,and strong immunogenicity,mRNA vaccines have played a pivotal role in the fight against the COVID-19 pandemic.So far,multiple mRNA vaccines against the SARS-COV-2 have been approved for marketing or authorized for emergency use.In addition,the research and industrialization of mRNA vaccines in areas such as other infectious diseases,tumor immunology have also become the focus of recent research.This paper provides an overview of the development status of mRNA vaccine research pipelines and supply chains,with the aim of offering references for the subsequent development and industrialization of mRNA vaccines.

关 键 词：mRNA疫苗 mRNA疫苗研产 大规模生产 供应链 产业化 

分 类 号：F426.72[经济管理—产业经济]